Vontobel Holding Ltd. Allakos Inc. Transaction History

Vontobel Holding Ltd.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jun 03, 2024	SELL	$1.72 - $3.18 $30,531 - $56,448	-17,751 Reduced 2.3%	752,381 $2.05 Million
Q4 2023 Jan 29, 2024	SELL	$1.72 - $3.18 $30,531 - $56,448	-17,751 Reduced 2.3%	752,381 $2.05 Million
Q3 2023 Jun 03, 2024	BUY	$2.13 - $5.55 $715,300 - $1.86 Million	335,822 Added 77.32%	770,132 $1.75 Million
Q3 2023 Oct 10, 2023	BUY	$2.13 - $5.55 $715,300 - $1.86 Million	335,822 Added 77.32%	770,132 $1.75 Million
Q2 2023 Jun 03, 2024	BUY	$3.6 - $5.25 $1.56 Million - $2.28 Million	434,310 New	434,310 $1.89 Million
Q2 2023 Jul 24, 2023	BUY	$3.6 - $5.25 $1.56 Million - $2.28 Million	434,310 New	434,310 $1.89 Million

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Vontobel Holding Ltd., based on Form 13F filings with the SEC.

Stay updated on Vontobel Holding Ltd. with notifications on news.